RAVE’s net cash cushions the franchise value, not the downside 2026-09 / week-4 Darden’s LongHorn strength does not yet offset Olive Garden’s gap 2026-09 / week-4 Cracker Barrel’s EBITDA guide prices a turnaround, not a traffic floor 2026-09 / week-4 General Mills beats Q1 estimates, but the volume recovery is still unproven 2026-09 / week-4 General Mills’ volume reset is not yet a 10/5 long 2026-09 / week-4 THOR's Q4 margin slump met a 5.5% rally, but the short fails 10/5 2026-09 / week-4 Cintas’ FY27 guide is healthy; its price still leaves no 10/5 margin 2026-09 / week-4 Worthington’s postmarket gap prices data-center demand before it reaches the margin bridge 2026-09 / week-4 MillerKnoll's tariff-adjusted earnings are weaker, but the short still fails 10/5 2026-09 / week-4 KB Home’s first backlog rise is not yet a demand inflection 2026-09 / week-4 GAUZ’s Appeal Can Preserve Trading Without Restoring Financial Visibility 2026-09 / week-4 AutoZone’s Q4 report tests margin and debt, but the pre-event short still fails 10/5 2026-09 / week-4 NWCL Starts With a $2.4B Nuclear Valuation and No Public Trading History 2026-09 / week-4 VWAV’s 1-for-20 Split Raises the Quote, Not the Common-Equity Value 2026-09 / week-4 KSCP’s $35M ATM Raises Cash, Not the Common-Equity Case 2026-09 / week-4 LABT’s Phase 2 Story Sits Behind a 100M-Share Authorization 2026-09 / week-4 INCY’s Australia Partnership Is Commercial Progress, Not a New 10% Earnings Case 2026-09 / week-4 CHGA’s Nasdaq Cure Removes a Listing Risk, Not the Equity Evidence Gap 2026-09 / week-4 ORBS’s $380M Treasury Headline Is Not a $380M Common-Equity Floor 2026-09 / week-4 GPUS Prices a $750M Campus Story Before the Sale or Cash Bridge Exists 2026-09 / week-3 GPUS.PD’s 13% Coupon Is Not a Credit Bridge 2026-09 / week-3 HYACU’s $10 SPAC Trust Is Optionality, Not a 10/5 Long 2026-09 / week-3 ABAT’s 407% Revenue Growth Still Sits Behind a $250M Dilution Door 2026-09 / week-3 Surgery Partners’ $797 million sale removes revenue before it removes the leverage risk 2026-09 / week-3 CLSK’s $2.276B Debt Raise Funds the Build-Out, Not the Equity Case 2026-09 / week-3 HUBG’s Nasdaq Delisting Notice Is a Filing Crisis, Not a Bargain 2026-09 / week-3 XCharge’s second-half revenue promise cannot support a safe short entry 2026-09 / week-3 LINC Expands a CMC Training Partnership, Not Its Earnings Base 2026-09 / week-3 RIG Adds $80 Million of Backlog; the Debt Bridge Still Dominates 2026-09 / week-3 Nucor’s Q3 guide reset tests a steel-price rally, but the short is already too late 2026-09 / week-3 MG’s $20.35 Takeout Offer Is a Spread, Not a 10/5 Long 2026-09 / week-3 OPTT Completes Army Surf-Zone Testing Without a Contract Award 2026-09 / week-3 OIG Priced Below Its Range; the IPO Still Needs an Insurance-Quality Proof 2026-09 / week-3 BBNX Raises $172.5 Million, but the Offering Price Is the First Benchmark 2026-09 / week-3 CoreWeave’s $3 billion convertible raise tests whether AI demand can outrun the capital stack 2026-09 / week-3 GCL Gets More Nasdaq Time, Not an Operating Turnaround 2026-09 / week-3 PUSA Prices a Defense Framework Before It Has Contract Economics 2026-09 / week-3 Ultragenyx’s FAYUVI approval leaves a launch short with a dangerous squeeze 2026-09 / week-3 AIFF Prices a Clinic Integration Before It Prices Contract Revenue 2026-09 / week-3 Scholar Rock Has FDA Approval; the Common Stock Still Has a Launch-Proof Problem 2026-09 / week-3 